Arvida Group Limited FY26 Result — Market Release, 28 May 2026
Arvida Group Limited
Provider claim
Community provider
2026-10-10
Next review: 2027-04-10
New Zealand company portfolio; financial year ended 31 March 2026
Medium confidence
verified
Primary-source research review
Evidence boundary: Two-page commercial issuer announcement; both pages inspected and visually checked. It describes audited results but contains no financial statements or independent auditor opinion. Underlying EBITDA is explicitly unaudited; its numeric reconciliation is not supplied. Rounded financial values, mixed suites/apartments, gross ORA resales and investment-property movement have different meanings. No numerical occupancy rate, survey method, clinical outcome study or current service-access guarantee is established. Demographic demand and housing-market outlook are forecasts/company views. Exact current NZX attachment matches preserved bytes; the legacy announcements.nzx.com attachment path returned404, so the discovered current public API URL is used. Original filename, category, PDF and June 2026 access preserved; reviewed 10 October 2026. This is a distinct source from doc-0194, not a duplicate annual report. No investment recommendation or current legal interpretation.
Short Answer
Two-page issuer results release linking unaudited underlying EBITDA, mixed care-suite/apartment completions and portfolio growth to the year ended March 2026; should be read with the full financial annual report, doc-0194.
Why it matters
Read this announcement alongside doc-0194 to compare headline company measures with the statutory statements, and to identify follow-up questions about actual care access and completed versus future capacity.
Key Points
- •Dated 28 May 2026, covering the financial year ended 31 March; exchange publication was 28 May at 08:32 NZST. PDF production metadata is 27 May. The original has two physical pages, not 11 (pp. 1–2; exchange payload).
- •The release’s rounded figures are net profit after tax $97 million, total assets $5.0 billion and equity $1.7 billion; exact audited figures and comparatives appear in doc-0194 (p. 1).
- •Underlying EBITDA of $133 million is reported as 10% higher and explicitly unaudited non-GAAP. The footnote lists exclusions/additions, without a numeric reconciliation in this release (p. 1).
- •Gross value of ORAs resold was $303 million; this is not the company’s care-service revenue or a measure of cash retained after refunds and costs (p. 1).
- •Investment-property carrying value rose by $335 million to $4.5 billion. That total movement includes development activity and should not be equated with fair-value revaluation alone (p. 1; doc-0194 p. 17).
- •Bethlehem Shores completions comprise 55 care suites and 53 premium apartments. The mixed 108 total must not be recorded as 108 care beds (p. 1).
Full Summary & Notes
Two-page issuer results release linking unaudited underlying EBITDA, mixed care-suite/apartment completions and portfolio growth to the year ended March 2026; should be read with the full financial annual report, doc-0194.
Open the full summary for detailed notes and source links.
This two-page market release is dated 28 May 2026 and summarises Arvida’s financial year ended 31 March 2026. NZX’s publication payload records 08:32 NZST that day; the PDF’s 27 May production metadata is separate. The current exchange attachment matches the preserved June 2026 original byte for byte. It is a concise issuer announcement, not an annual report, care audit or independent sector study.
The release reports rounded net profit after tax of $97 million, assets of $5.0 billion and equity of $1.7 billion. Its $133 million underlying EBITDA, described as 10% higher, is explicitly unaudited non-GAAP; the footnote describes adjustments rather than providing a numeric reconciliation. Gross ORA resales of $303 million are a transaction measure rather than care-service revenue. The $335 million increase in investment-property carrying value should not be mistaken for the fair-value gain alone.
The company reports completion of 55 care suites and 53 premium apartments at Bethlehem Shores and describes high care occupancy without a numerical rate, site denominator or independent care-quality evidence. The profile reports 34 retirement villages and notes the November 2024 Stonepeak acquisition. These are dated company statements; its demand and housing-market outlook is forward-looking.
Use the release to locate the original results and ask how care delivery, development and financial measures relate. The companion annual report, doc-0194, supplies exact financial figures and audit scope, including a decline in reported profit and operating cash flow despite the adjusted-EBITDA increase. This release does not verify current vacancies, contracts, clinical outcomes or future demand.
Read bundled source notes
The saved source file may include fuller notes and references than the indexed summary. Check its dates and evidence limits.
Loading saved source notes…
Document Details & Metadata
Related Resources
Four-page May 2026 issuer release on reported care occupancy, adjusted earnings, planned Karori acquisition, new-build care projects and home-support expansion; forecast capacity and promotional service claims require separate verification.
FY2024 care operator report on high-acuity beds, employee and resident feedback, RConnect staffing, community activity, new home-support plans and audited financial results; 49 PDF spreads contain the numbered report through page 95.
42-page FY2026 financial annual report with a short portfolio and leadership overview, audited statements, valuation and resident-loan notes, planned development and limited resident-feedback reporting; separate from the two-page results release.
The report brings together a corporate portfolio overview, strategy, resident experience, workforce and environmental initiatives, audited consolidated financial statements and remuneration/governance reporting. Its accounts report a statutory loss despite improved adjusted operating earnings and positive aggregate free cash flow; the existing-operations component of that cash flow remains negative. Restated FY25 values and the note 2 reconciliation are essential for comparisons. Use the company’s dated care occupancy and portfolio figures to frame questions, with mature-site and cross-country boundaries retained. Organisation-wide team members are not clinical staffing FTE; NPS and participation scores lack detailed survey denominators. Testimonials, product roll-outs and training claims are commercial narrative rather than independently evaluated clinical evidence. Future construction, demographic assertions and dividend/funding expectations require separate subsequent verification.
Report-based reconciliation of a June 2026 source brief. Original authored publication date is known only to year 2026; 5 June dates the annual report, not necessarily the brief. Detailed narrative retains historical strategy and June news context while correcting report contradictions; analyst reaction, subsequent bond events and later role/project outcomes are not independently checked in this scoped review.
Historical FY2024 operator report on care occupancy, resident and employee feedback, development, audited financial statements, climate scenarios and governance; underlying profit and care-quality narrative have separate assurance limits.